Skip to main content
Erschienen in: BMC Endocrine Disorders 1/2017

Open Access 01.12.2017 | Case report

Case report: schwannoma arising from the unilateral adrenal area with bilateral hyperaldosteronism

verfasst von: Naru Babaya, Yukako Makutani, Shinsuke Noso, Yoshihisa Hiromine, Hiroyuki Ito, Yasunori Taketomo, Kazuki Ueda, Hokuto Ushijima, Yoshifumi Komoike, Yuto Yamazaki, Hironobu Sasano, Yumiko Kawabata, Hiroshi Ikegami

Erschienen in: BMC Endocrine Disorders | Ausgabe 1/2017

Abstract

Background

We report a rare case of a juxta-adrenal schwannoma that could not be discriminated from an adrenal tumor before surgical resection and was complicated by bilateral hyperaldosteronism. To the best of our knowledge, this is first case in which both a juxta-adrenal schwannoma and hyperaldosteronism co-existed.

Case presentation

A 69-year-old male treated for hypertension was found to have a left supra-renal mass (5.8 × 5.2 cm) by abdominal computed tomography. His laboratory data showed that his plasma aldosterone concentration (PAC) was within the normal range, but his plasma renin activity (PRA) was reduced, resulting in an increased aldosterone/renin ratio (ARR). Load tests of captopril or furosemide in the standing position demonstrated autonomous aldosterone secretion and renin suppression. Adrenal venous sampling (AVS) with ACTH stimulation indicated bilateral hypersecretion of aldosterone. A left supra-renal tumor was resected because of the possibility of malignancy and was found to be a benign schwannoma arising from the juxta-adrenal region together with an adrenal gland. The dissected left adrenal gland was morphologically hyperplastic in the zona glomerulosa, but was immunohistochemically negative for CYP11B2 (aldosterone synthase). Multiple CYP11B2-positive adrenocortical micronodules were detected in the adrenal gland, indicating micronodular hyperplasia. Although bilateral aldosteronism was indicated by AVS before the operation, the PRA, PAC and ARR values were within their respective reference ranges after resection of the unilateral tumor, suggesting that the slight increase in hormone secretion from the remaining right-sided lesion could not be detected after resection.

Conclusion

A clinical and morphologic diagnosis of juxta-adrenal schwannoma is difficult, particularly in a case of hyperaldosteronism, as shown in this case. These data suggest the complexity and difficulty diagnosing adrenal incidentaloma.
Abkürzungen
ARR
Aldosterone/renin ratio
AVS
Adrenal venous sampling
CT
Computed tomography
DH
Diffuse hyperplasia
HE
Hematoxylin and eosin
IHA
Idiopathic hyperaldosteronism
MRI
Magnetic resonance imaging
PAC
Plasma aldosterone concentration
PRA
Plasma renin activity
WI
Weighted images

Background

A schwannoma is a benign, encapsulated and slowly progressive tumor originating from the nerve sheath. It occurs predominantly in the head and neck region as well as in the flexor surfaces of the upper and lower extremities [1]. Retroperitoneal schwannomas are rare [2, 3]. In particular, a visceral schwannoma in the adrenal region is extremely rare. Juxta-adrenal and adrenal schwannomas may cause non-specific clinical symptoms as symptoms and laboratory data specific to this particular disease have not been defined. The low incidence and asymptomatic nature of the disease with no hormonal production make a definitive diagnosis of schwannoma in the adrenal region difficult, leading to misinterpretation of the mass as an adrenal adenoma or cancer [2]. Surgery is typically required to establish a diagnosis and for treatment.
We treated a 69-year-old male patient with a juxta-adrenal schwannoma that could not be diagnosed preoperatively.

Case presentation

Our patient is a 69-year-old Japanese man. At the age of 55 years, he underwent a medical assessment for occasional left abdominal pain. A left suprarenal mass was discovered by abdominal computed tomography (CT), and he was referred to our hospital. The tumor was 4 cm in size at that time, and no hormonal production had been detected (plasma renin activity (PRA), 0.5 ng/mL/h; plasma aldosterone concentration (PAC), 105 pg/mL; aldosterone/renin ratio (ARR), 210; the load test of furosemide in the standing position (PRA of 2.3 ng/mL/h, PAC of 236 pg/mL, ARR of 102.6); normal catecholamine and cortisol levels). Consequently, a diagnosis of a non-functional adrenal tumor was determined. The patient did not want to undergo surgery and was followed without surgical excision. The follow-up at our hospital continued for 5 years, and the tumor size (4.5 × 3.8 cm) did not appear to be increasing (the CT scan from the final visit is shown in Fig. 1a).
At the age of 65 years, he experienced an acute myocardial infarction and was taken to another hospital. Afterwards, he periodically visited the hospital for cardiac function assessments and hypertension treatment. At the age of 69 years, he was referred to our hospital because of a left suprarenal mass identified on abdominal CT (Fig. 1b) as part of a regular medical examination for ischemic heart disease and hypertension. He was admitted to our hospital for a detailed evaluation because the tumor had increased in size (5.8 × 5.2 cm). On admission, he was apparently in good health with no symptoms. He had been taking an antihypertensive drug (Amlodipine besylate 2.5 mg/day). A physical examination revealed no significant findings. His blood pressure was 136/76 mmHg. The laboratory data are shown in Table 1. The complete blood count and blood biochemistry tests were within normal ranges. The endocrinological data were within the normal range except for abnormal PRA and ARR values. The PAC was within the normal range (66 pg/mL), but PRA was reduced (0.2 ng/mL/h), resulting in an increased ARR (330).
Table 1
Laboratory data
Peripheral blood
Endocrinological data
Load test
 WBC
5630/mm3
(3300–8600)
[plasma]
  
[captopril]
  
 RBC
410 × 104/mm3
(435–555)
 Epinephrine
< 5 pg/mL
(0–100)
 Renin
0 min
0.3 ng/mL/h
 Hb
13.0 g/dL
(13.7–16.8)
 Norepinephrine
69 pg/mL
(100–450)
 
60 min
< 0.1 ng/mL/h
 Ht
38.9%
(40.7–50.1)
 Dopamine
13 pg/mL
(0–20)
 
90 min
< 0.1 ng/mL/h
 Plt
13.8 × 104/mm3
(15.8–34.8)
 Renin
0.2 ng/mL/h
(0.3–2.9)
 Aldosterone
0 min
84.7 pg/mL
   
 Aldosterone
66 pg/mL
(29.9–159)
 
60 min
77.1 pg/mL
Biochemical data
  
 ARR
330
(< 200)
 
90 min
72.7 pg/mL
 T.P.
6.6 g/dL
(6.6–8.1)
 ACTH
24.5 pg/mL
(7.2–63.3)
   
 Alb
4.2 g/dL
(4.1–5.1)
 Cortisol
11.1 μg/dL
(6.2–19.4)
[furosemide with upright position]
 T.Bil
0.8 mg/dL
(0.4–1.5)
 DHEA-S
100 μg/dL
(24–244)
 Renin
0 min
0.3 ng/mL/h
 AST
18 U/L
(13–30)
    
30 min
0.5 ng/mL/h
 ALT
15 U/L
(10–42)
[urine]
   
60 min
0.7 ng/mL/h
 LDH
207 U/L
(124–222)
 Epinephrine
5.5 μg/day
(3.4–26.9)
 
120 min
0.9 ng/mL/h
 ALP
149 U/L
(106–322)
 Norepinephrine
97.9 μg/day
(48.6–168.4)
 Aldosterone
0 min
70.1 pg/mL
 rGTP
20 U/L
(13–64)
 Dopamine
932.6 μg/day
(365–961.5)
 
30 min
154 pg/mL
 BUN
16 mg/dL
(8–20)
 Aldosterone
4.7 μg/day
(0–10)
 
60 min
177 pg/mL
 Crea
0.84 mg/dL
(0.65–1.07)
 Cortisol
45.3 μg/day
(11.2–80.3)
 
120 min
203 pg/mL
 Na
140 mEq/L
(138–145)
      
 K
4.0 mEq/L
(3.6–4.8)
      
 Cl
108 mEq/L
(101–108)
      
 Glu
97 mg/dL
(73–109)
      
 T.chol
153 mg/dL
(142–220)
      
 HbA1c
5.8%
(4.9–6.2)
      
Reference ranges are in parentheses. The judgment criteria of the load tests are as reported in [4]
To evaluate autonomous secretion of aldosterone and suppression of renin, load tests of captopril or furosemide in the standing position were carried out according to guidelines [4]. In Japan, if the ARR is high, at least 2 of 3 confirmation tests are recommended to make a definitive diagnosis (load tests of captopril or furosemide in the standing position, or saline) before attempting localization by adrenal vein sampling (AVS) [4]. No increase in renin activity was observed in the load tests, indicating autonomous secretion of aldosterone.
AVS with ACTH stimulation indicated that the PAC in both adrenal veins was markedly high (Fig. 2). The PAC/cortisol ratio in both adrenal veins did not show laterality. These data demonstrate that both adrenal glands exhibited high and autonomous secretion of aldosterone, which is usually diagnosed as idiopathic hyperaldosteronism (IHA).
On CT scan (Fig. 1b), the left suprarenal mass was mostly circumscribed with a partial irregularity, and it was a homogenous mass (20~40 HU) with a density similar to that of the kidney (30~50 HU). The imaging diagnosis of the CT scan by the radiologist indicated an adrenal tumor. On magnetic resonance imaging (MRI), the tumor showed a low signal intensity on T1-weighted images (WI) (Fig. 1c) and heterogeneous signal intensity on T2-WI (Fig. 1d). Together with the results of MRI, the radiologist suggested that the tumor was a schwannoma.
Surgery was performed because of the possibility of malignancy, and a left supra-renal tumor was resected. On gross pathological examination (Fig. 3a), a clearly demarcated tumor (6.5 × 4.8 × 4.2 cm, 111 g) was observed with the adrenal gland and fat tissue. Histologically, the tumor was a typical schwannoma (Fig. 3b-e) and consisted of two different patterns of Antoni A and B components [5] without defined nuclear atypias. The Antoni A area had a high cellular density component characterized by closely packed spindle-shaped tumor cells with nuclear palisading, forming Verocay bodies, whereas the Antoni B area had a relatively low cellular density component with myxoid stroma. According to the immunohistochemical examination, the spindle-shaped tumor cells were strongly and diffusely positive for S-100 (Fig. 3d, e). Based on these histological findings, the tumor was diagnosed as a typical benign schwannoma.
Although the patient’s abdominal mass was a schwannoma adjacent to the adrenal gland, the preoperative examination could not detect whether the lesion was responsible for autonomous aldosterone hypersecretion. Therefore, we performed a histological analysis of the adrenal gland (Fig. 4). The dissected left adrenal gland was morphologically hyperplastic in the zona glomerulosa, but was immunohistochemically negative for CYP11B2 (aldosterone synthase [6, 7]), demonstrating “paradoxical hyperplasia” [7, 8] (Fig. 4a). Multiple CYP11B2-positive adrenocortical micronodules were detected in the resected adrenal gland (Fig. 4a, b), and these micronodules were negative for CYP11B1 (Fig. 4c). These histological findings demonstrated that the lesion responsible for autonomous aldosterone hypersecretion in the present case was derived from unilateral adrenocortical micronodules [7] rather than diffuse hyperplasia (DH) [7].
The postoperative course of the patient was uneventful. The patient is presently well and has shown no signs of recurrence of the schwannoma as of 6 months after the operation. His blood pressure is 110–130/70–90 mmHg with the administration of an antihypertensive drug (Amlodipine besylate 2.5 mg/day). His blood biochemistry data, including potassium, are within the normal range. His endocrinological data are also within the normal range, including the PAC (25.5 pg/mL), PRA (0.5 ng/mL/h) and ARR (51.0).

Discussions

A schwannoma is usually a benign tumor emerging from a peripheral nerve sheath. A schwannoma in the adrenal gland is very rare [1, 9] and typically originates from the adrenal medulla. High levels of urinary catecholamine have been reported in several cases [3, 10]. Schwannomas of the retroperitoneum, especially the juxta-adrenal region, may be misdiagnosed as primary adrenal lesions [2] because of their shape. The remarkable aspect of our case is that aldosteronism was present in addition to the tumor, which led us the misdiagnosis of a primary adrenal tumor. Because of the tumor’s large size (5.8 × 5.2 cm) and slow growth over several years, surgical excision was chosen based on the recommendation that surgical removal should be considered for non-functional adrenal masses larger than 4 cm [5, 11]. Retroperitoneal nerve sheath tumors can be malignant and are potentially fatal, so it is important to remove retroperitoneal tumors completely [5].
In this case, the co-occurrence of a schwannoma and aldosterone-producing micronodules is considered to be incidental, but the possibility that humoral factors secreted from the schwannoma may have affected aldosterone secretion cannot be fully excluded. No case of a schwannoma and concurrent bilateral autonomous aldosterone-producing lesions in the same patient has been reported in the literature, including schwannomas arising from places other than the retroperitoneum. However, the etiologies of these non-neoplastic autonomous aldosterone-producing lesions in the adrenal gland remain unknown, and further investigations are required for clarification.
After the operation, the patient had normal blood pressure with the administration of an antihypertensive drug (Amlodipine besylate 2.5 mg/day). His PRA, PAC and ARR values were within the reference ranges even though bilateral aldosteronism was indicated by AVS before the operation, possibly because slight changes in hormone secretion from the remaining right-sided lesion cannot be detected in the peripheral blood. A careful follow-up of the hormone levels and a pathological examination of a right-sided adrenal lesion, if present, are needed to clarify this supposition. Yamazaki et al. reported that all bilateral cases of aldosteronism have similar pathological features in both the right and left adrenals (18 out of 18 cases) [7]. Therefore, we suppose that the right adrenal gland may have unilateral adrenocortical micronodules and will need to be followed carefully.

Conclusions

Preoperative diagnosis of a juxta-adrenal schwannoma is difficult, especially in a case with hyperaldosteronism. To the best of our knowledge, this is first case in which both a juxta-adrenal schwannoma and hyperaldosteronism co-existed, demonstrating the complexity and difficulty of the diagnosis of adrenal incidentaloma.

Acknowledgements

Not applicable.

Funding

No funding was required for this work.

Availability of data and materials

All data contained within the article.
Not applicable.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Mohiuddin Y, Gilliland MG. Adrenal schwannoma: a rare type of adrenal incidentaloma. Arch Pathol Lab Med. 2013;137:1009–14.CrossRefPubMed Mohiuddin Y, Gilliland MG. Adrenal schwannoma: a rare type of adrenal incidentaloma. Arch Pathol Lab Med. 2013;137:1009–14.CrossRefPubMed
2.
Zurück zum Zitat Damodaran S, Mahimairaj G, Velaichamy K. A case series of two cases of juxta-adrenal schwannoma presenting as adrenal mass lesion and review of the literature. Urol Ann. 2015;7:254–8.CrossRefPubMedPubMedCentral Damodaran S, Mahimairaj G, Velaichamy K. A case series of two cases of juxta-adrenal schwannoma presenting as adrenal mass lesion and review of the literature. Urol Ann. 2015;7:254–8.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Moriwaki Y, Miyake M, Yamamoto T, Tsuchida T, Takahashi S, Hada T, Nishigami T, Higashino K. Retroperitoneal ganglioneuroma: a case report and review of the Japanese literature. Intern Med. 1992;31:82–5.CrossRefPubMed Moriwaki Y, Miyake M, Yamamoto T, Tsuchida T, Takahashi S, Hada T, Nishigami T, Higashino K. Retroperitoneal ganglioneuroma: a case report and review of the Japanese literature. Intern Med. 1992;31:82–5.CrossRefPubMed
4.
Zurück zum Zitat Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A. Task force committee on primary Aldosteronism TJES. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J. 2011;58:711–21.CrossRefPubMed Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A. Task force committee on primary Aldosteronism TJES. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J. 2011;58:711–21.CrossRefPubMed
5.
Zurück zum Zitat Lee NJ, Hruban RH, Fishman EK. Abdominal schwannomas: review of imaging findings and pathology. Abdom Radiol (NY). 2017; Lee NJ, Hruban RH, Fishman EK. Abdominal schwannomas: review of imaging findings and pathology. Abdom Radiol (NY). 2017;
6.
Zurück zum Zitat Nanba K, Tsuiki M, Sawai K, Mukai K, Nishimoto K, Usui T, Tagami T, Okuno H, Yamamoto T, Shimatsu A, Katabami T, Okumura A, Kawa G, Tanabe A, Naruse M. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry. J Clin Endocrinol Metab. 2013;98:1567–74.CrossRefPubMed Nanba K, Tsuiki M, Sawai K, Mukai K, Nishimoto K, Usui T, Tagami T, Okuno H, Yamamoto T, Shimatsu A, Katabami T, Okumura A, Kawa G, Tanabe A, Naruse M. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry. J Clin Endocrinol Metab. 2013;98:1567–74.CrossRefPubMed
7.
Zurück zum Zitat Yamazaki Y, Nakamura Y, Omata K, Ise K, Tezuka Y, Ono Y, Morimoto R, Nozawa Y, Gomez-Sanchez CE, Tomlins SA, Rainey WE, Ito S, Satoh F, Sasano H. Histopathological classification of cross-sectional image-negative Hyperaldosteronism. J Clin Endocrinol Metab. 2017;102:1182–92.PubMed Yamazaki Y, Nakamura Y, Omata K, Ise K, Tezuka Y, Ono Y, Morimoto R, Nozawa Y, Gomez-Sanchez CE, Tomlins SA, Rainey WE, Ito S, Satoh F, Sasano H. Histopathological classification of cross-sectional image-negative Hyperaldosteronism. J Clin Endocrinol Metab. 2017;102:1182–92.PubMed
8.
Zurück zum Zitat Sasano H, Okamoto M, Sasano N. Immunohistochemical study of cytochrome P-450 11 beta-hydroxylase in human adrenal cortex with mineralo- and glucocorticoid excess. Virchows Arch A Pathol Anat Histopathol. 1988;413:313–8.CrossRefPubMed Sasano H, Okamoto M, Sasano N. Immunohistochemical study of cytochrome P-450 11 beta-hydroxylase in human adrenal cortex with mineralo- and glucocorticoid excess. Virchows Arch A Pathol Anat Histopathol. 1988;413:313–8.CrossRefPubMed
9.
Zurück zum Zitat Kasperlik-Zaluska AA, Roslonowska E, Slowinska-Srzednicka J, Otto M, Cichocki A, Cwikla J, Slapa R, Eisenhofer G. 1,111 patients with adrenal incidentalomas observed at a single endocrinological center: incidence of chromaffin tumors. Ann N Y Acad Sci. 2006;1073:38–46.CrossRefPubMed Kasperlik-Zaluska AA, Roslonowska E, Slowinska-Srzednicka J, Otto M, Cichocki A, Cwikla J, Slapa R, Eisenhofer G. 1,111 patients with adrenal incidentalomas observed at a single endocrinological center: incidence of chromaffin tumors. Ann N Y Acad Sci. 2006;1073:38–46.CrossRefPubMed
Metadaten
Titel
Case report: schwannoma arising from the unilateral adrenal area with bilateral hyperaldosteronism
verfasst von
Naru Babaya
Yukako Makutani
Shinsuke Noso
Yoshihisa Hiromine
Hiroyuki Ito
Yasunori Taketomo
Kazuki Ueda
Hokuto Ushijima
Yoshifumi Komoike
Yuto Yamazaki
Hironobu Sasano
Yumiko Kawabata
Hiroshi Ikegami
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
BMC Endocrine Disorders / Ausgabe 1/2017
Elektronische ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-017-0225-z

Weitere Artikel der Ausgabe 1/2017

BMC Endocrine Disorders 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.